Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Currently approved weight management pharmacotherapy in the UK includes: Semaglutide (Wegovy) a GLP-1 receptor agonist approved by the MHRA for chronic weight management in adults, subject to NICE Technology Appraisal eligibility criteria [3] [5] Tirzepatide (Mounjaro) a dual GIP/GLP-1 receptor agonist approved by the MHRA for the treatment of type 2 diabetes
Consider skipping the prior authorization process entirely
In the U.S., it is classified as a medical supply rather than a controlled drug
ABOUT THE AUTHORTavishi Dogra Tavishi Dogra is a Deputy Chief Content Producer, Health & Wellness, at Hindustan Times
HSA & FSA accepted Treatment is only provided if a licensed provider determines it may be appropriate after review
US$ 24.48
US$ 29.43
US$ 25.37
US$ 22.80
US$ 28.51
